Drugs / OLENDALIZUMAB
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01883544 | Jun → Dec 2013 | — | Alexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02245412 | Nov 2014 → Feb 2017 | acute graft versus host disease | Alexion Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT02128269 | Apr 2014 → Jun 2016 | antiphospholipid syndrome | Alexion Pharmaceuticals, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01454986 Comparator | Nov 2011 → Aug 2013 | — | Alexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OLENDALIZUMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL3990025 ↗ |
| Known as | ALXN1007 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01883544 ↗ |
| Known as | ALXN1007 antibody | ChEMBL registry synonym — accepted as the source's own label CHEMBL3990025 ↗ |
| Known as | Lendalizumab | ChEMBL registry synonym — accepted as the source's own label CHEMBL3990025 ↗ |
| Action | Inhibit | “ALXN1007 (a C5a inhibitor)” NCT02245412 ↗1“Complement C5 inhibitor” CHEMBL3990025 ↗ |
| Modality | Monoclonal antibody | “recombinant humanized monoclonal antibody” NCT02245412 ↗ |
| Route | Intravenous | “Single dose, IV” NCT01454986 ↗ |
| Target | C5 | “Complement C5 inhibitor” CHEMBL3990025 ↗ |